STUDY PROTOCOL
Accepted on 18 Mar 2025
Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): A prospective, single-arm, exploratory Study
doi 10.3389/fimmu.2025.1542877